As the first week of July comes to an end we take a look over the most popular stories of the previous seven days.
While a series of scandals have drawn some of the big names into a web of legal issues, this week has offered a glimpse of hope as progress is made in innovative new treatments.
Our top story focuses on the legal action being undertaken by the State of Massachusetts against those responsible for marketing Purdue Pharma’s OxyContin. However as Trump lashes out against big pharma we discuss the exciting discoveries being made in the fight against Parkinson’s and HIV.
Check out the week’s ten most popular articles on Pharmafile.com now!
A US Judge has ordered pharmaceutical company AbbVie to pay $448 million after determining that the company had used sham litigation in an effort to delay generic versions of the testosterone replacement drug AndroGel from getting to market.
It’s a big step forward for AstraZeneca’s global marketing operations as the company announced that two of its products have received approval in Japan in the treatment of two key cancers.
Despite threats from President Trump, Pfizer has just hefted the price of 40 of its drugs in its second round of hikessince the beginning of the year. The US firm has bolstered the price tags of around 100 of its products this year.
Novartis has announced a plan to spinoff Alcon – its eye care division – into a separately-traded standalone company.
Roche’s sometimes strained relationship with NICE continues as the health watchdog for England and Wales chose to reject the former’s humanised anti-CD20 monoclonal antibody Ocrevus (ocrelizumab) in the treatment of early primary progressive multiple sclerosis (MS).
Cadila Healthcare has announced that it has gained FDA final approval to market Nifedipine ER tablets and cholestyramine oral suspension.
The drug, which is similar to compounds used to treat diabetes, could be one of the first treatments to directly target the progression of the degenerative condition.
The Brussels-based pharmaceutical company UCB has announced that the European Medicines Agency (EMA) has approved a label extension for Cimzia (certolizumab pegol), to include a new indication in adult patients with moderate-to-severe plaque psoriasis.
Biotechnology firm Abivax has lifted the curtain on new Phase 2a data for its HIV therapy ABX464, showing that the drug was able to reduce levels of the virus’ DNA in blood and rectal tissue.Top of Form
The state of Massachusetts has taken action to sue a board member at GlaxoSmithKline for her alleged role in fuelling the opioid addiction crisis that has devastated the United States in recent years.